Talis Biomedical Corporation (TLIS) |
|
0.8139 -0.029 (-3.45%)
|
06-26 19:25 |
|
Open: |
0.84 |
Pre. Close: |
0.843 |
|
High:
|
0.8998 |
Low:
|
0.8 |
|
Volume:
|
1,549,657 |
Market Cap:
|
22(M) |
|
|
|
|
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.9 - 0.91 |
0.91 - 0.91 |
|
Low:
|
0.79 - 0.79 |
0.79 - 0.8 |
|
Close:
|
0.81 - 0.81 |
0.81 - 0.82 |
|
Technical analysis |
as of: 2022-06-24 4:43:40 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.13  One year: 1.26 |
| Support: |
Support1: 0.8 Support2: 0.66 |
| Resistance: |
Resistance1: 0.97 Resistance2: 1.08 |
| Pivot: |
0.92 |
| Moving Average: |
MA(5): 0.84 MA(20): 0.94
MA(100): 1.37 MA(250): 4.35 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 12.1 %D(3): 12.6  |
| RSI: |
RSI(14): 30.5 |
| 52-week: |
High: 12.88 Low: 0.8 |
| Average Vol(K): |
3-Month: 185 (K) 10-Days: 322 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TLIS ] has closed above bottom band by 12.8%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 19 Jun 2022
Talelma Lift Irrigation Scheme to be inaugurated today - The Hindu
Wed, 08 Jun 2022
Bio-Rad Laboratories (NYSE:BIO.B) and Talis Biomedical (NASDAQ:TLIS) Financial Survey - Defense World
Sun, 15 May 2022
Talis Biomedical Corporation(TLIS) CEO Rob Kelly on Q12022 Results - Earnings Call Transcript - Seeking Alpha
Wed, 11 May 2022
Talis Biomedical Corporation (TLIS) Q1 2022 Earnings Call Transcript - The Motley Fool
Tue, 10 May 2022
Can Talis Biomedical (NASDAQ:TLIS) Afford To Invest In Growth? - Yahoo Finance
Tue, 26 Apr 2022
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022 - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
0 (M) |
| Shares Float |
26 (M) |
|
% Held by Insiders
|
9.82e+006 (%) |
|
% Held by Institutions
|
10.3 (%) |
|
Shares Short
|
550 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.9024e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
341.2 |
|
Return on Equity (ttm)
|
-51.7 |
|
Qtrly Rev. Growth
|
8.19e+006 |
|
Gross Profit (p.s.)
|
-2.92 |
|
Sales Per Share
|
0.28 |
|
EBITDA (p.s.)
|
-7.87 |
|
Qtrly Earnings Growth
|
-13.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-171 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
2.82 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
705060 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
